Adma Biologics 

$10.18
221
-$0.07-0.68% Today

Statistics

Day High
10.34
Day Low
9.85
52W High
23.71
52W Low
8.29
Volume
1,162,936,196
Avg. Volume
-
Mkt Cap
2.42B
P/E Ratio
17.53
Dividend Yield
-
Dividend
-

Upcoming

Earnings

6MayExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
0.13
0.16
0.19
0.21
Expected EPS
0.193333
Actual EPS
N/A

Financials

28.8%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
1.02BRevenue
293.86MNet Income

Analyst Ratings

22.5Average Price Target
The highest estimate is 24.00.
From 3 ratings within the last 6 months. This is not an investment recommendation.
Buy
67%
Hold
33%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ADMA. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Takeda Pharmaceutical
TAK
Mkt Cap52.51B
Takeda Pharmaceutical Company, through its plasma-derived therapies and subunit vaccines, competes in similar therapeutic areas as ADMA.
Carlisle Companies
CSL
Mkt Cap14.45B
CSL Behring operates in the plasma protein biotherapeutics area, directly competing with ADMA's immune globulin products.
Grifols SA
GRFS
Mkt Cap5.6B
Grifols, S.A. specializes in plasma-derived biopharmaceuticals, offering products that overlap with ADMA's portfolio.
Biomarin Pharmaceutical
BMRN
Mkt Cap10.45B
BioMarin Pharmaceutical focuses on rare diseases treated by genetic and plasma-derived therapies, competing in the same niche as ADMA.
Pfizer
PFE
Mkt Cap149.77B
Pfizer has a broad portfolio that includes immunoglobulin therapies, competing with ADMA in the immune globulin market.
GSK
GSK
Mkt Cap103.01B
GlaxoSmithKline produces vaccines and plasma-derived medicinal products, making it a competitor in ADMA's market space.
Abbvie
ABBV
Mkt Cap365.43B
AbbVie, with its biopharmaceutical products, competes in the immunology and plasma-derived therapeutic areas relevant to ADMA.
AMGEN
AMGN
Mkt Cap178B
Amgen's focus on innovative therapeutics and biologics in areas like immunology poses competition to ADMA's product offerings.
Biogen
BIIB
Mkt Cap27.62B
Biogen's portfolio includes therapies for neurological and autoimmune diseases, competing with ADMA in the specialty biologics space.
Johnson & Johnson
JNJ
Mkt Cap546.9B
Johnson & Johnson, through its pharmaceutical segment, offers products that compete with ADMA's immunoglobulin and plasma-based therapies.

About

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. The company also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
Show more...
CEO
Mr. Adam S. Grossman
Employees
685
Country
United States
ISIN
US0008991046

Listings

0 Comments

Share your thoughts

FAQ

What is Adma Biologics stock price today?
The current price of ADMA is $10.18 USD — it has decreased by -0.68% in the past 24 hours. Watch Adma Biologics stock price performance more closely on the chart.
What is Adma Biologics stock ticker?
Depending on the exchange, the stock ticker may vary. For instance, on exchange Adma Biologics stocks are traded under the ticker ADMA.
Is Adma Biologics stock price growing?
ADMA stock has fallen by -3.96% compared to the previous week, the month change is a +9.7% rise, over the last year Adma Biologics has showed a -55.97% decrease.
What is Adma Biologics market cap?
Today Adma Biologics has the market capitalization of 2.42B
What is Adma Biologics revenue for the last year?
Adma Biologics revenue for the last year amounts to 1.02B USD.
What is Adma Biologics net income for the last year?
ADMA net income for the last year is 293.86M USD.
How many employees does Adma Biologics have?
As of May 06, 2026, the company has 685 employees.
In which sector is Adma Biologics located?
Adma Biologics operates in the Health & Wellness sector.
When did Adma Biologics complete a stock split?
Adma Biologics has not had any recent stock splits.
Where is Adma Biologics headquartered?
Adma Biologics is headquartered in Ramsey, United States.